Skip to main content
Signal8

T2 Biosystems, Inc. (TTOO)

T2 Biosystems, Inc. is an in vitro diagnostics company that develops and commercializes innovative diagnostic solutions for global markets. Its proprietary technology platform enables the rapid detection of pathogens, biomarkers, and other critical abnormalities directly from a wide array of unpurified patient specimens, including whole blood, plasma, serum, saliva, sputum, cerebrospinal fluid, and urine. The company's commercial offerings include the T2Dx Instrument, a compact bench-top system designed to run various diagnostic assays. Its current suite of diagnostic tests features T2Candida, a direct-from-blood test that rapidly identifies bloodstream infections leading to sepsis and candidemia; T2Bacteria, another direct-from-blood assay for detecting bacterial pathogens commonly associated with sepsis; T2Resistance, which targets and identifies genes conferring carbapenem resistance; and the T2SARS-CoV-2 panel, developed to detect the SARS-CoV-2 virus. In addition to its existing products, T2 Biosystems is actively advancing several diagnostic candidates. These include T2Biothreat, aimed at identifying biothreat pathogens; a comprehensive sepsis panel designed to detect bloodstream infections caused by both bacterial and Candida species, along with antibiotic resistance markers; T2Cauris, which offers direct detection of the emerging superbug Candida auris in patient skin, blood, and hospital environmental samples; and T2Lyme, a direct-from-blood test panel specifically engineered for the T2Dx Instrument to identify the bacteria responsible for Lyme disease. T2 Biosystems has also established strategic partnerships, such as its collaboration with Canon U.S. Life Sciences, Inc., to jointly develop a diagnostic test panel for Lyme disease. The company was founded in 2006 and is headquartered in Lexington, Massachusetts.

Sector: Medical - Diagnostics & Research

Industry: Medical - Diagnostics & Research

T2 Biosystems, Inc. logo

T2 Biosystems, Inc.

OTC:TTOOHealthcare
$0.0004
CLOSED
Mkt Cap$11K
EV-
Float28.05M
O/S28.05M
VOL1K sh
$ Vol$2
RVOL0.07×
Inst Own0.0%
SI<0.1%
Net Cash/Sh-
Dilution
T2 Biosystems, Inc. logoOTC:TTOOClosed$0.0004
Short interest (FINRA)
0.0%
Oct 30 (18d)

Float 28.05M · Signal8 estimate from ownership filings · Nov 4, 2026

4.9K
Oct 30 (18d)prev 4.9K– 0.0%
1.00
Oct 30 (18d)prev 1.00– 0.0%
Borrow (IBKR)

The cost to borrow TTOO shares for a short sale and how many IBKR has available, from IBKR's lendable-stock file, refreshed through the session.

IBKR borrow fee and availability is included in Signal8 ProUpgrade to Pro · $40.67/mo billed annually
Off-exchange & settlement
3.1%
Nov 13 (4d)prev 17.4%▼ 14.3 pts

Off-exchange short volume is not short interest and is not a bearish signal. When a wholesaler fills a retail buy order it sells to the customer as principal and buys back in the market, and that sale is reported as short. A high reported short share is therefore characteristic of internalised retail buying, and this figure should not be read as investors positioning against the stock.

No fails on record for 16–31 Oct 2026.
Price, short interest & fails to deliver
Short interest · today's share basis23 settlements
Latest short interest settlements (today's share basis)
DateShares short
Oct 30, 20264.9K sh
Oct 15, 20264.9K sh
Sep 30, 20264.9K sh
Sep 15, 20264.9K sh
Aug 31, 20264.9K sh

A stock split executed inside this window; every settlement plotted has been carried onto today’s share basis, so the line does not step at the split.

The three panels share one date axis, so a point's position is its date; each has its own value axis. Short interest is plotted on today's share basis, so the line does not step where a split does.

Off-exchange short volume
Nov 13
Latest sessions
DateReported short
Nov 13, 20263.1%
Nov 12, 202617.4%
Nov 11, 20260.2%
Nov 9, 202629.8%
Sep 24, 202635.7%
8-session median 32.8%mean 34.1%range 0.2–99.8%

130 calendar days requested; 9 sessions published. FINRA reports this at T+1 to T+2, so the latest session is not today's.

Source: FINRA Reg SHO daily short volume, summed across the NASDAQ, NYSE and Consolidated trade reporting facilities. Covers off-exchange (over-the-counter) executions only; volume executed on an exchange is not included and is not reported short here.

Off-exchange short volume is not short interest and is not a bearish signal. When a wholesaler fills a retail buy order it sells to the customer as principal and buys back in the market, and that sale is reported as short. A high reported short share is therefore characteristic of internalised retail buying, and this figure should not be read as investors positioning against the stock.

ATS venues (dark pools)

FINRA's weekly alternative trading system (dark pool) volume for TTOO: the share of off-exchange volume that traded on an ATS, and each venue by shares and trades.

The ATS venue breakdown is included in Signal8 ProUpgrade to Pro · $40.67/mo billed annually

As of the Oct 30, 2026 FINRA settlement, 4,916 TTOO shares were sold short (0.02% of a 28.05M-share float, 1.00 days to cover).